BioPharm March eBook - Outsourcing Resources

Issue link:

Contents of this Issue


Page 32 of 34 March 2018 BioPharm International eBook 33 Outsourcing Resources Market Investment Contract Services Investment Update A review of the latest investments in facilities, equipment, and acquisitions by biopharma contract service providers. AMBER LOWRY B iopharmaceutical contract service providers have advanced their capabilities and offer- ings to help their clients tackle industry challenges and accelerate innovations. The following are some of the latest investments in facilities and equipment by contract service provid- ers, as well as the mergers and acquisitions market. MERGERS AND ACQUISITIONS Charles River Laboratories International announced on Feb. 13, 2018 that it has entered into a definitive agreement to acquire MPI Research for approximately $800 million in cash, expanding its early-stage con- tract research offerings for the biopharmaceutical and medical device markets (1). MPI, a Mattawan, MI-based non-clinical contract research organization (CRO), provides comprehen- sive testing services from its one-million-ft2 facility. The acquisition will add ototoxicity and abuse liabil- ity capabilities to Charles River's services and will increase existing capabilities in general and specialty toxicology, including ophthalmology, juvenile toxic- ity, molecular biology, and surgery, as well as medical device testing, as stated by Charles River. The statement also reports the strategic benefits of Charles River expanding its biotechnology client base, Gajus/

Articles in this issue

Links on this page

Archives of this issue

view archives of BioPharm - BioPharm March eBook - Outsourcing Resources